- Home
- IMNM vs ACP Comparison
IMNM vs ACP Comparison
Compare IMNM & ACP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- ACP
- Stock Information
- Founded
- IMNM 2006
- ACP 2010
- Country
- IMNM United States
- ACP United States
- Employees
- IMNM N/A
- ACP N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- ACP Investment Managers
- Sector
- IMNM Health Care
- ACP Finance
- Exchange
- IMNM Nasdaq
- ACP Nasdaq
- Market Cap
- IMNM 748.3M
- ACP 695.1M
- IPO Year
- IMNM 2020
- ACP N/A
- Fundamental
- Price
- IMNM $9.06
- ACP $5.85
- Analyst Decision
- IMNM Strong Buy
- ACP
- Analyst Count
- IMNM 5
- ACP 0
- Target Price
- IMNM $26.40
- ACP N/A
- AVG Volume (30 Days)
- IMNM 973.9K
- ACP 337.9K
- Earning Date
- IMNM 05-12-2025
- ACP 01-01-0001
- Dividend Yield
- IMNM N/A
- ACP 17.79%
- EPS Growth
- IMNM N/A
- ACP N/A
- EPS
- IMNM N/A
- ACP N/A
- Revenue
- IMNM $10,938,000.00
- ACP N/A
- Revenue This Year
- IMNM N/A
- ACP N/A
- Revenue Next Year
- IMNM $542.22
- ACP N/A
- P/E Ratio
- IMNM N/A
- ACP N/A
- Revenue Growth
- IMNM N/A
- ACP N/A
- 52 Week Low
- IMNM $5.15
- ACP $5.55
- 52 Week High
- IMNM $16.81
- ACP $7.17
- Technical
- Relative Strength Index (RSI)
- IMNM 61.94
- ACP 56.27
- Support Level
- IMNM $8.50
- ACP $5.68
- Resistance Level
- IMNM $9.04
- ACP $5.88
- Average True Range (ATR)
- IMNM 0.54
- ACP 0.07
- MACD
- IMNM 0.09
- ACP -0.00
- Stochastic Oscillator
- IMNM 90.18
- ACP 68.00
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.